PMID- 11892903
OWN - NLM
STAT- MEDLINE
DCOM- 20020823
LR  - 20090804
IS  - 1120-009X (Print)
IS  - 1120-009X (Linking)
VI  - 14
IP  - 1
DP  - 2002 Feb
TI  - Three-times weekly teicoplanin in the outpatient treatment of acute 
      methicillin-resistant staphylococcal osteomyelitis: a pilot study.
PG  - 71-5
AB  - Treatment of osteomyelitis requires prolonged hospital stay, lengthy antibiotic 
      therapy and adequate surgical debridement. Outpatient parenteral antibiotic 
      therapy (OPAT) is a new approach to reduce patient discomfort and hospital costs. 
      Teicoplanin, a glycopeptide antibiotic with a long half-life (72 hours), is one 
      of the most useful drugs for OPAT. We performed a pilot study to assess the 
      safety and efficacy of three-times weekly teicoplanin in the treatment of 
      methicillin-resistant (MR) acute staphylococcal osteomyelitis. Ten patients with 
      acute post-traumatic osteomyelitis were enrolled. Pathogens were MR 
      Staphylococcus aureus (5 patients) and MR coagulase-negative staphylococci (5 
      patients). After a loading dose of 400 mg b.i.d. for 3 days, patients were 
      treated with an intravenous dose of 1000 mg on Mondays and Wednesdays and with a 
      1200 mg dose on Fridays. Teicoplanin trough levels were maintained within a 10 to 
      20 mg/L range. If hardware removal had been possible at enrollment, treatment was 
      carried out for at least 4 weeks. If, on the contrary, hardware removal had not 
      been possible, teicoplanin was administered as suppressive therapy until hardware 
      removal. Treatment was successfully performed in 9 out of 10 patients, whereas in 
      one patient only improvement was achieved. Side effects were not recorded. Three 
      times weekly teicoplanin seems to be a valuable option in the treatment of acute 
      MR staphylococcal osteomyelitis. Further studies are warranted in order to better 
      define the role of this new administration schedule in this field.
FAU - Lazzarini, L
AU  - Lazzarini L
AD  - Department of Infectious and Tropical Diseases, Ospedale S. Bortolo, Vicenza, 
      Italy. fdl.vi@gpnet.it
FAU - Tramarin, A
AU  - Tramarin A
FAU - Bragagnolo, L
AU  - Bragagnolo L
FAU - Tositti, G
AU  - Tositti G
FAU - Manfrin, V
AU  - Manfrin V
FAU - de, Lalla F
AU  - de LF
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Chemother
JT  - Journal of chemotherapy (Florence, Italy)
JID - 8907348
RN  - 0 (Anti-Bacterial Agents)
RN  - 61036-62-2 (Teicoplanin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Anti-Bacterial Agents/*administration & dosage
MH  - Cost Savings
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - *Methicillin Resistance
MH  - Middle Aged
MH  - Osteomyelitis/*drug therapy
MH  - Outpatients
MH  - Pilot Projects
MH  - Staphylococcal Infections/*drug therapy
MH  - Teicoplanin/*administration & dosage
EDAT- 2002/03/15 10:00
MHDA- 2002/08/24 10:01
CRDT- 2002/03/15 10:00
PHST- 2002/03/15 10:00 [pubmed]
PHST- 2002/08/24 10:01 [medline]
PHST- 2002/03/15 10:00 [entrez]
AID - 10.1179/joc.2002.14.1.71 [doi]
PST - ppublish
SO  - J Chemother. 2002 Feb;14(1):71-5. doi: 10.1179/joc.2002.14.1.71.